DNL343 Falls Short of Primary End Point in Phase 2/3 HEALEY-ALS Platform Trial

Over a 24-week period, DNL343 failed to distinguish itself from placebo on the primary end point of ALSFRS-R, as well as on other secondary end points of muscle strength and respiratory function.:

Source: Neurology Read More